|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM16606422X |
| 003 |
DE-627 |
| 005 |
20250207171510.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0554.xml
|
| 035 |
|
|
|a (DE-627)NLM16606422X
|
| 035 |
|
|
|a (NLM)17049310
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Garg, Sanjay K
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Does sphingosine 1-phosphate play a protective role in the course of pulmonary tuberculosis?
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.01.2007
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Sphingosine 1-phosphate (S1P) has recently been reported to induce antimycobacterial activity in vitro and in a mouse model of in vivo Mycobacterium tuberculosis infection. However, its role in the course of pulmonary tuberculosis in humans is still not known. This study shows that S1P levels in airway surface fluid of tuberculosis (TB) patients are significantly less than those observed in non-TB control patients. Moreover, the in vitro stimulation of bronchoalveolar lavage cells coming from TB patients with S1P significantly reduces intracellular growth of endogenous mycobacterial isolates. These results show that, in the course of pulmonary TB, airway epithelial fluid-associated S1P may play a protective role in the containment of intracellular mycobacterial growth and that its decrease may represent a novel pathogenic mechanism through which M. tuberculosis favors its replication
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Lysophospholipids
|2 NLM
|
| 650 |
|
7 |
|a sphingosine 1-phosphate
|2 NLM
|
| 650 |
|
7 |
|a 26993-30-6
|2 NLM
|
| 650 |
|
7 |
|a Sphingosine
|2 NLM
|
| 650 |
|
7 |
|a NGZ37HRE42
|2 NLM
|
| 700 |
1 |
|
|a Santucci, Marilina B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Panitti, Miriam
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pucillo, Leo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bocchino, Marialuisa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okajima, Fumikazu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bisen, Prakash S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Saltini, Cesare
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fraziano, Maurizio
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 121(2006), 3 vom: 01. Dez., Seite 260-4
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:121
|g year:2006
|g number:3
|g day:01
|g month:12
|g pages:260-4
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 121
|j 2006
|e 3
|b 01
|c 12
|h 260-4
|